India's Gland Pharma said on Thursday U.S. private equity firm KKR & Co LP had agreed to invest about $200 million to buy a minority stake in the company.

KKR will acquire the minority stake in Gland Pharma, including the entire stake held by private equity fund, Evolvence India Life science Fund, in the Hyderabad-based firm, KKR said in a statement.

Gland Pharma develops and manufactures generic injectables primarily for the U.S. market, and also for India and other semi-regulated markets.

Follow us on Twitter: @ALB_Magazine.

Related Articles

Other News

Korea’s Lee & Ko adds arbitration veteran to head int’l disputes

by Sarah Wong |

South Korean law firm Lee & Ko has significantly enhanced its dispute resolution capabilities with the appointment of international arbitration expert Park Eun Young as head of the firm's international disputes group.

Other News

Kim & Chang maintains top spot in Korean M&A legal advisory

by Asian Legal Business《亚洲法律杂志》 |

South Korea's largest law firm, Kim & Chang, has retained its leading position in the country's mergers and acquisitions (M&A) legal advisory market for the first nine months of 2023, according to data released on Oct. 3.

Other News

Drew secures $3.5 bln judgment against Lim family in Hin Leong case

by Asian Legal Business《亚洲法律杂志》 |

Singapore Big Four law firm Drew & Napier has successfully represented liquidators in securing a $3.5 billion judgment against former oil tycoon Lim Oon Kuin, known as OK Lim, and his two children in Singapore's largest reported fraudulent trading case.